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Background:  Immunization  programs  currently  measure  coverage  by assessing  the  proportion  of  children
12–24 months  who  have  been  immunized  but  this  does  not  address  the  important  question  of  when  the
scheduled  vaccines  were  administered.  Data  capturing  the  timing  of  vaccination  in ﬁrst  6 months,  when
severe  disease  is  most likely  to  occur,  are  limited.
Objective: To  estimate  the  time  to Bacillus  Calmette–Guérin  (BCG)  (recommended  at  birth),
diphtheria-tetanus-pertussis-H,  inﬂuenza  b-hepatitis  B (DTP-Hib-HepB),  and oral  polio  vaccine  (OPV)
(recommended  at 6,  10,  and  14  weeks)  vaccinations  and  risk  factors  for vaccination  delay  in  infants  <6
months of age  in a district  in  southern  Nepal  where  traditional  coverage  metrics  are  high.
Design/methods:  Infants  enrolled  in  a randomized  controlled  trial  of  maternal  inﬂuenza  vaccination  were
visited  weekly  at home  from  birth  through  age 6 months  to ascertain  if  any  vaccinations  had  been  given  in
the  prior  week.  Infant,  maternal,  and household  characteristics  were  recorded.  BCG,  DTP-Hib-HepB,  and
OPV vaccination  coverage  at 4 and  6 months  was  estimated.  Time  to  vaccination  was estimated  through
Kaplan–Meier  curves;  Cox-proportional  hazards  models  were  used  to examine  risk  factors  for  delay  for
the ﬁrst  vaccine.
Results:  The  median  age  of  BCG,  ﬁrst  OPV  and  DTP-Hib-HepB  receipt  was  22,  21, and  18  weeks,  respec-
tively.  Almost  half  of infants  received  no BCG  by age  6  months.  Only  8% and  7% of  infants  had  received
three  doses  of  OPV  and  DTP-Hib-HepB,  respectively,  by  age  6 months.
Conclusion:  A  signiﬁcant  delay  in receipt  of  infant  vaccines  was  found  in  a prospective,  population-based,
cohort  in southern  Nepal  despite  traditional  coverage  metrics  being  high.  Immunization  programs  should
consider  measuring  time  to  receipt  relative  to  the  ofﬁcial  schedule  in  order  to maximize  beneﬁts  for
disease  control  and  child health.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license∗ Corresponding author. Tel.: +1 3145402499.
E-mail addresses: michelle.hughes@jhu.edu (M.M.  Hughes), jkatz@jhu.edu
J. Katz), Janet.englund@seattlechildrens.org (J.A. Englund), skhatry@wlink.com.np
S.K. Khatry), laxmanshree@yahoo.com (L. Shrestha), steveleclerq@gmail.com
S.C. LeClerq), mark.steinhoff@cchmc.org (M.  Steinhoff), jtielsch@gwu.edu
J.M. Tielsch).
ttp://dx.doi.org/10.1016/j.vaccine.2015.12.061
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Immunization is the primary means of prevention for several
childhood infectious diseases. Approximately 2–3 million deaths
are prevented each year due to immunization with diphtheria,
tetanus, pertussis, and measles vaccines [1]. Since the introduction
of the Expanded Programme on Immunization (EPI) in 1974 the
percentage of children protected against six diseases (tuberculosis,
diphtheria, tetanus, pertussis, polio, and measles) increased from
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table 1
Nepal immunization schedule during study period May  2011–April 2014.
Vaccine Age of administration
BCG At birth
DTP-Hib-HepB 6 weeks, 10 weeks, 14 weeks
OPV 6 weeks, 10 weeks, 14 weeks
MR  9 months
JE  12–23 months (high risk districts)34 M.M. Hughes et al. / V
% to 83% (measured at 12–23 months of age) [2–4]. For exam-
le, the World Health Organization (WHO) estimates that since
he end of the 1980s, 80% of children worldwide received pertussis
accines, preventing approximately 38 million cases and 600,000
eaths annually [5]. Despite tremendous progress, global cover-
ge remains below the target of 90% diphtheria-tetanus-pertussis-3
DTP3) coverage [6]. While EPI has dramatically reduced the inci-
ence of vaccine-preventable diseases they remain an important
ontributor to child deaths in low and middle-income countries
7].
Delay in vaccination is especially important for infants who
re generally at high risk for severe morbidity and mortality from
hese diseases [8]. While infants might have partial protection from
assive transfer of antibodies from their mothers, this immunity
ventually wanes, requiring active immunization for infants to be
rotected against disease [9].
In Nepal, DTP3 vaccine coverage increased from 54% of chil-
ren fully vaccinated by 12–23 months of age in 1995 to 90% in
012; similar increases were seen for oral polio vaccine-3 (OPV3)
50–90%) and Bacillus Calmette–Guérin (BCG) (76–96%) [10]. Even
hough current coverage is high, this measure does not capture the
iming of vaccine receipt relative to the ofﬁcial schedule. Recent
stimates of coverage at 6 months in low and middle-income
ountries found DTP3 coverage was just 36% and BCG coverage was
5% [11]. A focus on vaccine receipt as close as possible to the ofﬁcial
chedule could signiﬁcantly improve the beneﬁts of immunization
rograms. Unfortunately, population-based data on early vaccina-
ion coverage using active surveillance in low-income countries are
acking. This prospective, population-based cohort study aimed to
stimate vaccination timing and risk factors for delay in the ﬁrst 6
onths of life in a rural district in southern Nepal. This informa-
ion is important for policy makers to understand potential delays
n vaccination and which populations are most at risk for targeted
nterventions to improve timeliness of uptake.
. Methods
.1. Settings and population
The setting of the study was in nine northern Village Develop-
ent Committee areas in Sarlahi District, located in the central terai
low lying plains) region of Nepal and nested within a randomized
ontrolled trial of maternal inﬂuenza vaccination during pregnancy
12]. At the start of the trial, prevalent pregnancies were identi-
ed through a census of all households in the catchment area. For
he duration of the trial, ﬁeld workers visited all households in the
ommunity where married women (15–40 years) resided every 5
eeks for surveillance of incident pregnancies. Once a pregnancy
as identiﬁed women were asked for their consent to participate
n the trial. Through the house-to-house surveillance, 4632 preg-
ancies were identiﬁed. Of these, 14 women were lost to follow-up
efore enrollment, 19 refused, 105 lost their fetus before enroll-
ent, 799 were identiﬁed >34 weeks gestation (primarily at the
eginning of the study), 1 had an egg allergy, and 1 intended to leave
he study area and thus was not eligible. Between April 25, 2011
nd September 9, 2013, 3693 pregnant women between 17 and
4 weeks gestation were randomized and vaccinated with either
n inﬂuenza vaccine or placebo. All participants received ancillary
eneﬁts, which included a 90-day supply of iron-folic acid tablets,
eworming medication (single dose of albendazole), clean birthing
it, chlorhexidine ointment for umbilical cord care, tetanus toxoid
accine, if indicated, and health education messages, in addition to
eferral for antenatal services in the local health care system. At the
ime of the study, the vaccines recommended by the Nepal vacci-
ation program in the ﬁrst 6 months were BCG (at birth), OPV andTT During pregnancy
Vitamin A 6–59 months
DTP-Hib-HepB (both at 6, 10, and 14 weeks) (Table 1). This study
was a population-based prospective cohort of infants followed from
birth through 6 months post-partum. Ethical approval for the study
was obtained from institutional review boards at the Johns Hop-
kins Bloomberg School of Public Health, the Institute of Medicine
at Tribhuvan University, and Cincinnati Children’s Medical Center.
The trial is registered at Clinicaltrials.gov (NCT01034254).
2.2. Data collection
At baseline, information was  collected on household structure,
socioeconomic status, and demographics. At study enrollment, date
of last menstrual period and pregnancy history data were col-
lected. As soon as possible after delivery the mother and infant
were visited to collect detailed birth information including infant
weight and breastfeeding status. From birth through 6 months
post-partum (180 days), infants were visited weekly by a ﬁeld
worker who recorded, based on maternal report, which speciﬁc
vaccines were received in the prior 7 days. BCG is given at birth
and usually results in a scar. OPV and pentavalent vaccine have
the same recommended timing but differ in their administration
route. The mothers reported only the type of vaccine received (not
the number of the dose as this was calculated during the analysis).
The ﬁeld workers maintained vaccine receipt data only for the cur-
rent month and therefore were not able to assess or address delays
in vaccination in the ﬁeld.
2.3. Analytic dataset
Infants were included in this analysis if they were followed for
any length (0–180 days) during an approximately 3 year-period.
Of 3693 women  vaccinated, there were 3621 women  with at least
one live birth outcome. There were 3646 live born infants, 50 of
whom were live-born twins and one live-born twin associated with
a stillbirth. No weekly vaccination recall data were collected for 169
infants (∼5%). The ﬁnal dataset consists of 3478 infants with at least
one follow-up visit during the ﬁrst 6 months.
Households were categorized as crowded if 5 or more people
resided in the home (median number of household members). Sim-
ilarly, households were dichotomized at the median into those with
>2 children under 15 years versus households with 2 or fewer chil-
dren under 15 years. At enrollment women reported their literacy
status (binary) and pregnancy history. For parity analysis women
were categorized as nulliparous or multiparous. The ﬁeld work-
ers identiﬁed the subject’s ethnicity (Pahadi – a group originating
from the hills or Madeshi – a group originating from north India).
Twenty-ﬁve questions were asked to develop a construct to mea-
sure the socioeconomic status of households. The questions were
the following: (1–3) construction materials for ground ﬂoor, ﬁrst
ﬂoor, and roof, (4) number of living and sleeping rooms, (5) water
source, (6) type of latrine, (7) number of servants, (8–9) number
of cattle and goats, (10–11) amount of khet and bari (measures of
rain fed and irrigation fed arable land owned), (12–17) number of
bullock carts, bicycles, motorcycles, cars/jeeps, trucks/buses, trac-
tors, (18–23) number of clocks, radios, televisions, satellite dishes,
accine
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andline phones, mobile phones, (24) electricity in home, and (25)
ousehold member working in another country. Responses for each
f the 25 questions were dichotomized. The SES variable was the
ercent of items on the 25-item scale that were positive. If any items
ere missing, the score was the percent positive out of the num-
er of non-missing items. These percentages were divided into SES
uartiles for analysis. Analyses using other cut-offs of SES produced
imilar results to quartiles.
Gestational age was measured using a woman’s report of date
f last menstrual period during pregnancy surveillance (an aver-
ge of 3–4 weeks recall). Gestational ages <37 complete weeks
ere categorized as preterm. Birthweight was collected as soon
s possible after birth by study personnel using a digital scale
Tanita model BD-585, precision to nearest 10 g]. Birthweights
ollected >72 h after birth were excluded from the analysis of birth-
eight. Infants were categorized as low birthweight if weight was
2500 grams (g). Small for gestational age (SGA) was  calculated
sing the sex-speciﬁc 10th percentile cut-off described by Alexan-
er [13] and the INTERGROWTH-21st standards [14]. Women  were
sked how many hours after birth breastfeeding was initiated (if at
ll). Binary breastfeeding categories were created with women  ini-
iating breastfeeding within 1 h (WHO recommendation) compared
o those initiating >1 h post-delivery.
.4. Statistical analysis
To ensure all infants included had an opportunity to have
ecorded vaccinations at the recommended vaccination ages, for
his analysis (excluding BCG, which is recommended at birth),
nfants were excluded if their lengths of follow up were less than
 months (16 weeks) after birth (Table 1). Vaccine coverage was
alculated at approximately 4 (2 week grace period after the ﬁnal
ecommended vaccination age) and 6 months (end of study follow-
p) (speciﬁcally, 112 and 180 days, respectively). The primary
utcome was the proportion of infants in each vaccination dose
ategory at 4 and 6 months.
Survival analysis was  used to measure the time to vaccination
or each vaccine by dose. Infants were included irrespective of
ength of follow-up. Kaplan–Meier curves were constructed with a
peciﬁc vaccination considered the event of interest. Infants were
ight-censored once they had the event of interest (speciﬁc vaccine
ose) or had no further follow-up recorded.
Infant, maternal, and household risk factors for time to 1st BCG,
TP-Hib-HepB (pentavalent), and OPV vaccination were analyzed
sing a Cox-proportional hazards model. The recommended age
Fig. 1. Infant immunization coverage at 4 and 6 month 34 (2016) 933–941 935
of ﬁrst pentavalent and OPV vaccination dose, 42 days, was  desig-
nated as time 0. Infants who  were vaccinated prior to 42 days were
assigned a date of vaccination immediately after time 0 (1 × 10−6).
The same adjustment made for loss-to follow-up was made for
those infants with no follow-up after 42 days. Infants who had at
least one follow-up visit but died before 42 days were excluded
from the analysis. Day of birth was  used as time 0 for BCG as this
vaccine is recommended at birth. For the unadjusted model, hazard
ratios, 95% conﬁdence intervals (CI), and p-values were reported.
Risk factors measuring similar characteristics were excluded to
avoid collinearity in the multivariate model. For the related vari-
ables – gestational age, birthweight, and SGA – only gestational
age and SGA were included in the multivariate model. The pro-
portionality assumption was tested through graphical diagnostics
and testing based on scaled Schoenfeld residuals [15]. Time inter-
action terms were included for time-varying coefﬁcients that were
statistically signiﬁcantly associated with time to vaccination in the
bivariate model. The multivariable model included adjusted hazard
ratios, 95% CIs and p-values.
Statistical signiﬁcance was  set at p < 0.05 for all testing. All statis-
tical analyses were conducted in Stata/SE 14.0 (STATA Corp., College
Station, TX).
3. Results
In this study, 3478 infants were visited at least once from birth
through 180 days of life. The visit dates ranged from May  24, 2011
to April 29, 2014. The mean age at last follow-up visit was 167
days (range: 3–180 days). The average length of follow-up was 156
days. For DTP-Hib-HepB (pentavalent) and OPV vaccination cov-
erage estimates, 168 infants were excluded due to having no data
at or beyond 4 months (2 weeks past the recommended age of 3rd
infant vaccine dose). Common reasons for no further follow-up past
age four months included death, a temporary move of the mother
and her newborn to her mother’s house, or a permanent move from
the study area. Altogether, 3310 infants were observed to at least
age 4 months. Of these included infants, 23% (n = 752) had received
no vaccinations of any type by age six months.
The majority (70%) of infants had received no pentavalent
immunization by age 4 months, two weeks past the recommended
age for completion of all 3 doses (Fig. 1). By age 6 months, 42%
of infants had received no pentavalent vaccinations, with only 7%
fully vaccinated by 6 months. An even higher percentage (76%) of
infants had no OPV vaccination by 4 months with a minority (8%)
s. *Excludes infants not observed past 4 months.
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ully vaccinated by age 6 months. By age 6 months only half (49%)
f children had received a BCG vaccine, which is recommended at
irth. A minority of infants were vaccinated prior to the recom-
ended vaccination ages. For pentavalent vaccine 3%, 0.2%, and 0%
eceived the ﬁrst, second, and third doses early, respectively. For
PV early vaccination receipt was found for 5%, 0.2%, and 0.03% for
he ﬁrst, second, and third doses, respectively.
The median age at ﬁrst DTP-Hib-HepB vaccination, estimated
sing survival curves, was  18.3 weeks (95% CI: 17.6–19.1) (Fig. 2).
he median age of ﬁrst OPV was 21.1 weeks (95% CI: 20.0–22.1);
CG median was 21.9 weeks (95% CI: 19.6–23.7).
Cox proportional hazard models were used to estimate the
elative hazard of being unvaccinated in unadjusted (bivari-
ble) and adjusted (multivariable) models (Tables 2–4). Highly
Fig. 2. Time to immunization. *Stars indicate thee 34 (2016) 933–941
collinear or related variables were excluded from the adjusted
models.
For time to ﬁrst pentavalent dose, the strongest associations
in the bivariable models were for ethnicity (HR 1.34; 95% CI:
1.22–1.48), delayed breastfeeding initiation (HR 1.19; 95% CI:
1.08–1.31) and number of children under 15 years for infants older
than 10 weeks (HR 1.43; 95% CI: 1.14–1.80) (Table 2). In the mul-
tivariable model ethnicity, breastfeeding, and number of children
under 15 years for the period when infants were >10 weeks of age
remained statistically signiﬁcant.For time to ﬁrst OPV dose, the strongest associations for high-
est hazard of being unvaccinated in bivariable models were for
high number of children <15 years (HR 1.21; 95% CI: 1.09–1.34)
and maternal illiteracy (Table 3). Maternal illiteracy increased
 recommended age for each vaccine dose.
M.M. Hughes et al. / Vaccine 34 (2016) 933–941 937
Table  2
Risk factors for delay in time to ﬁrst DTP-HepB-Hib vaccination.
Risk factor No. % Cox proportional hazard model
Unadjusted Adjusted
HRa 95% CIb p-Valuec HR 95% CI p-Value
Sex
Female 1645 47%
Male 1829 53% 1.07 0.98–1.18 0.13 1.03 0.93–1.15 0.57
Gestational aged
Term 3045 88%
Preterm 428 12% 1.11 0.96–1.28 0.16 1.17 0.98–1.40 0.08
Birthweighte
Normal 2036 75%
Low birthweight 668 25% 1.14 1.01–1.28 0.04
Small-for-gestational agef
Non-SGA (IG) 1587 63%
SGA (IG) 939 37% 1.09 0.98–1.22 0.11
Non-SGA (A) 1427 52%
SGA (A) 1296 48% 1.11 1.00–1.23 0.05 1.09 0.97–1.22 0.13
Breastfeeding
Breastfed <1 h 1192 35%
Non-breastfed 1st hour 2168 65% 1.19 1.08–1.31 <0.01 1.16 1.04–1.29 0.01
Literacy
Literate 1967 61%
Illiterate 1250 39% 1.12 1.01–1.23 0.03 1.05 0.92–1.18 0.48
Parity
Non-ﬁrst pregnancy 2021 58%
First pregnancy 1446 42% 1.10 1.00–1.20 0.05 1.09 0.97–1.23 0.13
Ethnicity
Pahadi 1929 58%
Madeshi 1412 42% 1.34 1.22–1.48 <0.01 1.21 1.07–1.37 <0.01
SESg
Lower vs. higher 3342 1.02i 0.98–1.07 0.30
Crowdingh
Uncrowded 1817 55%
Crowded 1492 45% 0.98 0.89–1.07 0.64
Children under 15 years
Age 6–10 weeks
≤2 children 1895 57%
>2  children 1414 43% 1.05 0.94–1.17 0.38 1.02 0.90–1.16 0.72
Age  >10–26 weeks
≤2 children 1895 57%
>2  children 1414 43% 1.43 1.14–1.80 <0.01 1.45 1.11–1.90 <0.01
a Hazard ratio; interpretation: ratio of the hazard of being unvaccinated in risk group compared to the reference group.
b 95% conﬁdence interval.
c p-Values calculated from the Wald test of the maximum likelihood estimate (MLE) of the coefﬁcient.
d Gestational age: preterm (<37 weeks), term (≥37 weeks).
e Birthweight: low birthweight (<2500 g), normal (≥2500 g).
f Small-for-gestational age: IG = INTERGROWTH-21st standards; A = Alexander standards.
g Socioeconomic status (SES): average of 24 SES measures categorized into quartiles and modeled as a continuous variable (1–4).
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i Interpretation example: hazard of being unvaccinated in the bottom quartile co
he hazard of being unvaccinated by 3% per week of infant age
95% CI: 1–6%). In the multivariable model these two  factors
emained statistically signiﬁcantly associated with OPV vaccination
elay.
For time to ﬁrst BCG dose, the strongest factors associated with
 higher hazard of being unvaccinated in bivariable models were
or ethnicity (HR 1.26; 95% CI: 1.15–1.39) and illiteracy (HR 1.16;
5% CI: 1.05–1.29) (Table 4). Ethnicity was the only factor statis-
ically signiﬁcantly associated with BCG vaccination delay in the
ultivariate model. We  examined whether delivery location (hos-
ital/clinic versus home birth) was associated with delay (data not
hown) given BCG is recommended at birth; there was no associa-
ion between delivery location and BCG timing.
. DiscussionThe current approach to measuring coverage of immuniza-
ion programs by assessing the proportion of children immunized
mong those 12–23 months of age does not address the importantn household).
ed to 2nd lowest quartile.
question of when the scheduled vaccines were administered. In this
prospective, community-based study, delays in immunizations in
infants <6 months of age in Sarlahi District, Nepal, were common,
at a time when infants are at highest vulnerability for morbidity
from these infections. These signiﬁcant delays were not captured
by WHO  estimates of vaccination coverage. Nepal data from 2012
show DTP1 and DTP-Hib-HepB3, and OPV3 coverage all at 90%, and
BCG coverage at 96% among children age 12–23 months [16]. The
2011 Nepal Demographic and Health Survey (DHS) estimates vary
slightly from this with DTP1 and DTP3 coverage at 96% and 91%,
respectively [17]. OPV1 coverage was  97% versus 92% for OPV3.
BCG coverage was  97%. From the same 2011 survey, in the central
terai region, where Sarlahi District is located, 96%, 92%, and 87% of
children were reported to have received one, two, and three doses,
respectively, of DTP by ages 12–23 months [17]. Coverage for OPV1-
3 was  96%, 92%, and 89%, respectively. BCG coverage was 96%. While
these coverage estimates are high, our data show many infants
receive vaccines on a delayed schedule and thus are at increased
risk for vaccine-preventable diseases. Globally, WHO  and UNICEF
938 M.M. Hughes et al. / Vaccine 34 (2016) 933–941
Table 3
Risk factors for delay in time to ﬁrst OPV vaccination.
Risk factor No. % Cox proportional hazard model
Unadjusted Adjusted
HRa 95% CIb p-Valuec HR 95% CI p-Value
Sex
Female 1645 47%
Male 1829 53% 1.03 0.93–1.13 0.55 1.03 0.92–1.15 0.62
Gestational aged
Term 3045 88%
Preterm 428 12% 1.16 0.99–1.35 0.06 1.14 0.94–1.37 0.18
Birthweighte
Normal 2036 75%
Low birthweight 668 25% 1.07 0.94–1.22 0.30
Small-for-gestational agef
Non-SGA (IG) 1587 63%
SGA (IG) 939 37% 1.04 0.92–1.17 0.53
Non-SGA (A) 1427 52%
SGA (A) 1296 48% 1.09 0.97–1.21 0.14 1.10 0.98–1.24 0.12
Breastfeeding
Breastfed <1 h 1192 35%
Non-breastfed 1st hour 2168 65% 1.14 1.03–1.26 0.01 1.05 0.94–1.18 0.37
Literacy
Age  6 weeks
Literate 1967 61%
Illiterate 1250 39% 0.96 0.78–1.17 0.66 0.89 0.70–1.13 0.34
1  week increase in age
Literate 1967 61%
Illiterate 1250 39% 1.03 1.01–1.06 <0.01 1.03 1.00–1.06 0.03
Parity
Non-ﬁrst pregnancy 2021 58%
First pregnancy 1446 42% 0.96 0.87–1.06 0.43 0.99 0.88–1.12 0.93
Ethnicity
Age  6 weeks
Pahadi 1929 58%
Madeshi 1412 42% 1.17 0.96–1.43 0.13 1.20 0.94–1.54 0.15
1  week increase in age
Pahadi 1929 58%
Madeshi 1412 42% 1.03 1.00–1.05 0.02 1.01 0.98–1.04 0.51
SESg
Lower vs. higher 3342 1.02i 0.98–1.07 0.39
Crowdingh
Uncrowded 1817 55%
Crowded 1492 45% 1.00 0.90–1.10 0.95
Children under 15 years
≤2 children 1895 57%
>2  children 1414 43% 1.21 1.09–1.34 <0.01 1.13 1.00–1.28 0.05
a Hazard ratio; interpretation: ratio of the hazard of being unvaccinated in risk group compared to the reference group.
b 95% conﬁdence interval.
c p-Values calculated from the Wald test of the maximum likelihood estimate (MLE) of the coefﬁcient.
d Gestational age: preterm (<37 weeks), term (≥37 weeks).
e Birthweight: low birthweight (<2500 g), normal (≥2500 g).
f Small-for-gestational age: IG = INTERGROWTH-21st standards; A = Alexander standards.
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i Interpretation example: hazard of being unvaccinated in the bottom quartile co
se ofﬁcially reported data and sample survey data to measure vac-
ination coverage of children 12–23 months [3]. As a result, if there
re signiﬁcant delays in vaccination, but vaccines are complete by
ge 2, a child is still considered as vaccinated on schedule. Similarly,
n the U.S. and elsewhere, standard national reporting statistics
bscure delays during periods when infants are most at risk for
accine-preventable diseases [11,18–20]. National-level reporting
ay  also mask within-country variation in vaccination timeliness
11].
Our ﬁnding of signiﬁcant vaccination delay is consistent with
ata from other countries. For example, Japan’s reported DTP3 cov-
rage was 98% in 2013, however data from a representative city in
apan showed less than 50% DTP coverage by age 12 months [19].
n the U.S., a study found almost half of children had some delay
n receiving a DTaP vaccine dose and 16% were delayed in vaccine
eceipt for more than 6 months in the ﬁrst two years; 32% had somed modeled as a continuous variable (1–4).
n household).
ed to 2nd lowest quartile.
delay in receipt of poliovirus vaccine, with 9% at least 6 months
delayed [18] despite national DTP3 and poliovirus vaccine cover-
age over 90% in 2013 [21]. A longitudinal study in Ghana reported
that while DTP3 coverage was 95% at 12 months, only 10% of infants
were vaccinated within 1 week of the scheduled time (14 weeks);
the median delay for DTP3 was  4 weeks [22]. In the same study
BCG coverage was 98% at 1 year but only 38% of infants were vac-
cinated within the ﬁrst week of life; the median delay for BCG was
1.7 weeks; similar delays were found for one coastal Kenyan dis-
trict [23]. In an Indian study using vaccination card records only
31% of infants received DTP3 by 14 weeks [24]. A study examin-
ing the timing of vaccination in low and middle income countries,
based on surveys and imputed data, found at 6 months median
coverage was 82% (Interquartile Range [IQR]: 67–89%) for DTP1,
36% (IQR: 23–54) for DTP3, and 85% (IQR: 73–91) for BCG [11].
Our data from Sarlahi, Nepal of DTP1 (57%), DTP3 (7%), and BCG
M.M. Hughes et al. / Vaccine 34 (2016) 933–941 939
Table  4
Risk factors for delay in time to BCG vaccination.
Risk factor No. % Cox proportional hazard model
Unadjusted Adjusted
HRa 95% CIb p-Valuec HR 95% CI p-Value
Sex
Female 1645 47%
Male 1829 53% 0.96 0.88–1.06 0.45 0.92 0.83–1.03 0.13
Gestational aged
Term 3045 88%
Preterm 428 12% 1.12 0.97–1.30 0.12 1.08 0.91–1.28 0.38
Birthweighte
Normal 2036 75%
Low birthweight 668 25% 1.03 0.92–1.16 0.62
Small-for-gestational agef
Non-SGA (IG) 1587 63%
SGA (IG) 939 37% 1.04 0.93–1.16 0.51
Non-SGA (A) 1427 52%
SGA (A) 1296 48% 1.02 0.92–1.13 0.66 1.03 0.93–1.15 0.56
Breastfeeding
Breastfed <1 h 1192 35%
Non-breastfed 1st hour 2168 65% 1.14 1.04–1.26 0.01 1.05 0.94–1.18 0.36
Literacy
Literate 1967 61%
Illiterate 1250 39% 1.16 1.05–1.29 <0.01 1.08 0.96–1.22 0.22
Parity
Non-ﬁrst pregnancy 2021 58%
First pregnancy 1446 42% 1.01 0.92–1.11 0.81 0.96 0.86–1.08 0.52
Ethnicity
Pahadi 1929 58%
Madeshi 1412 42% 1.26 1.15–1.39 <0.01 1.17 1.04–1.33 0.01
SESg
Lower vs. higher 3342 1.01 0.97–1.05 0.74
Crowdingh
Uncrowded 1783 54%
Crowded 1529 46% 1.02i 0.93–1.13 0.63
Children under 15 years
≤2 children 1897 57%
>2  children 1415 43% 1.02 0.93–1.12 0.68 0.95 0.85–1.06 0.36
a Hazard ratio; interpretation: ratio of the hazard of being unvaccinated in risk group compared to the reference group.
b 95% conﬁdence interval.
c p-Values calculated from the Wald test of the maximum likelihood estimate (MLE) of the coefﬁcient.
d Gestational age: preterm (<37 weeks), term (≥37 weeks).
e Birthweight: low birthweight (<2500 g), normal (≥2500 g).
f Small-for-gestational age: IG = INTERGROWTH-21st standards; A = Alexander standards.
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49%) coverage at 6 months are lower than these estimates from
ther similar countries. An interpretation of this is that the rural
erai of Nepal may  have an increased vaccination delay compared to
ther parts of the country or similar countries. However, Sarlahi’s
accination coverage data, measured later at 12–23 months, are
omparable to that of Nepal as a whole. Survey and imputed data
n general may  lead to an overestimation of coverage. While the
eekly vaccination recall could have prompted parents to immu-
ize thus biasing our results in the direction of better timeliness, our
rospective weekly active surveillance data are potentially a more
recise and unbiased estimation of timing of vaccination coverage
han previous estimates.
Despite the vaccination delays found in our study, the National
mmunization Program is a high priority program in Nepal, with
he country already having achieved Millennium Development
oal 4 on child mortality reduction [25,26]. Immunization delay
s important as it leaves infants at risk for vaccine preventable dis-
ases potentially contributing to morbidity and mortality [7,27]. For
xample, children who are unimmunized or under immunized are
t increased risk for pertussis and pertussis hospitalization com-
ared to their more fully immunized peers [19,28–32].
In our multivariate models, Madeshi ethnicity was  associ-
ted with an approximately 20% increased hazard of delay ford modeled as a continuous variable (1–4).
n household).
ed to 2nd lowest quartile.
DTP-Hib-HepB1 and BCG vaccines. A high number of children in the
household was  a risk factor for delay in the ﬁrst pentavalent and
OPV vaccines with the effect of crowding increasing with increasing
age for pentavalent vaccine. Factors associated with only one vac-
cine combination were breastfeeding initiation for DTP-Hib-HepB1
and literacy for OPV1 with literacy’s association with OPV1 delay
increasing with infant age. One reason why these factors might con-
tribute to vaccination delay is that they are markers for decreased
access or utilization of health services. Mothers who have lower
utilization of antenatal care might have had less exposure to the
importance of early initiation of breastfeeding. Women of Madeshi
ethnicity have less mobility and empowerment, and are therefore
less likely to access health care resources for themselves and their
children. The demands of more than 2 children <15 years in a house-
hold might limit the time and resources available for well child
visits. Together, these factors might lower access to visits where
infants have an opportunity for vaccination. We  found no differ-
ence in vaccination status by sex, birth order (parity), and SES, of
which the latter two are in contrast to that found in the 2011 Nepal
DHS [17]. The lack of observed sex differences is generally consis-
tent with previous global studies [33] although Nepal’s neighbor,
India, has observed sex differences in vaccination coverage [34].
Surprisingly, for BCG we  saw no association between facility versus
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ome delivery location in vaccination timing demonstrating a fail-
re in the health system to vaccine infants while still in the delivery
acility.
Reasons for vaccination delay in low and middle-income
ountries include poor immunization supply, lack of access to
ealth services, and family characteristics [20,22,35]. Parents may
lso be hesitant to vaccinate or not view the costs involved with
accination worth the beneﬁt. Infants in Ghana who  were poorer,
ad less educated mothers, and lived in rural versus urban areas
ere signiﬁcantly more likely to delay vaccination compared to
rban infants whose mothers were educated and in a higher income
roups [22]. A study of 31 low and middle income countries also
ound that children in poorer families and families with more than
ne child were at increased risk for vaccination delay [20]. In the
.S. vaccination delay is associated with a mother who  is unmar-
ied, less educated, non-Hispanic black, and uses public vaccination
roviders [18]. In contrast to these studies, in our Nepal popu-
ation, low socioeconomic status was not a signiﬁcant predictor
n vaccination delay. Our ﬁndings are similar to previous ﬁndings
ith maternal literacy and number of children in the household
oth being signiﬁcant predictors of vaccination delay. Our study
rovides an improved understanding of Nepal-speciﬁc factors con-
ributing to vaccination delay that can help programs focus on
t-risk populations to increase on-time vaccination.
A limitation of our study is that our surveillance extended only
or the ﬁrst 6 months of life. We  were not able to capture the tim-
ng of vaccination receipt after age 6 months to age 12 months.
e cannot provide if or when vaccines were received to capture
he full delay. This limited the direct comparability of our data to
fﬁcial data reported at age 1 year. The most likely explanation
s that there is catch-up of vaccination beyond 6 months of age.
fﬁcial reporting in some countries may  overestimate the cover-
ge in part to reach donor targets such as GAVI’s immunization
ervices support (ISS) [3]. However, that study found that Nepal
id not over report its performance during the period when GAVI
ncentives were provided.
Another limitation of our study was that recording of vaccine
eceipt was reported by parents and not conﬁrmed by review of
mmunization cards. This could have led to misclassiﬁcation if
he parent reported an incorrect vaccine. However, the two  vac-
ines with the same schedule (OPV and pentavalent) differ in their
dministration (oral and injection) so this misreporting is unlikely.
t is possible BCG and pentavalent vaccines could have been con-
used, but BCG is given soon after birth, usually produces a typical
car not seen with other vaccines, and is done at a different injection
ite than pentavalent vaccine. Overestimation of coverage could
ave occurred if parents over reported vaccine receipt or underes-
imation if parents forgot or were unaware of a vaccine the infant
reviously received. However, parents were visited in their homes
n a weekly basis limiting the chance for recall bias.
Strengths of this study include the population-based cohort
tudy design that followed infants prospectively on a weekly basis
rom birth through age 6 months. The capture of time of vaccination
rovides important information for Nepal policy makers. While the
opulation was limited to one area of Sarlahi district in Nepal, the
esults are likely generalizable to much of the rural Nepalese popu-
ation. The majority of the Nepali population lives in the terai region,
here Sarlahi District is located and infant health and vaccination
ndictors are similar to country-wide estimates [17].
. ConclusionWe  found signiﬁcant delays in receipt of recommended infant
accinations in a prospective population-based cohort in southern
epal. The standard approach to immunization coverage estimates
[e 34 (2016) 933–941
worldwide does not fully capture the excess vaccine-preventable
disease risk attributable to delays in vaccination. Timeliness of
routine childhood immunization should be emphasized to reduce
infant morbidity and mortality risk from vaccine-preventable dis-
eases. Age appropriate vaccination indicators should be considered
as another metric of an immunization program’s impact.
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